TherapeuticsMD Q2 net loss narrows to $2.4M as royalty transition continues

TherapeuticsMD, Inc.

2023-Q2 EPS reported -$0.60 vs consensus -$0.07 ▼ miss (-740.3%)

Net loss from continuing ops of $2.4M ($0.24 per share) vs $14.9M ($1.70) in Q2 2022.
License and service revenue rose to $0.4M from $0.3M year-over-year, driven by Mayne License Agreement.
Total operating expenses fell 80.4% to $2.9M reflecting wind-down of manufacturing and commercial ops.
CEO says company is focused on cost reduction and cash conservation during ongoing business transformation.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TherapeuticsMD, Inc. reported second quarter ended June 30, 2023 results: revenue $0.4 million, net income $2.4 million, EPS $(0.24) per basic and diluted common share.

Period: second quarter ended June 30, 2023
Revenue: $0.4 million
Net income: $2.4 million
EPS: $(0.24) per basic and diluted common share
Result: reported results

Exact text from the filing

License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended June 30, 2023

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-211446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.